# Pharvaris N.V. (PHVS)

> Source: Nexqual · https://nexqual.com/PHVS · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Pharvaris N.V. (PHVS), nexqual.com/PHVS" · informational, not investment advice.

**Price:** USD 30.68 (+0.07% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 30.66 · day 29.85–31.02 · 52w 21.02–43.25 · market cap $2.15B · NMS

## Key facts
- 1 of 80 tracked superinvestors hold PHVS (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Total return with dividends: 1Y +33.4% vs S&P 500 +14.9%; 5Y +101.2% vs S&P 500 +80.3%.
- Next earnings: 2026-11-12, EPS estimate USD -0.72, revenue estimate $0K.

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold PHVS. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Viking Global | Viking Global Investors | 0.36% | $126M | Unchanged |

## Analysts
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-10 | Guggenheim | Target raised | Buy | $40 → $44 |
| 2026-09-09 | Morgan Stanley | Target raised | Overweight | $46 → $62 |
| 2026-09-09 | Leerink Partners | Target raised | Outperform | $50 → $65 |
| 2026-09-09 | Wells Fargo | Target raised | Overweight | $55 → $65 |
| 2026-09-09 | RBC Capital | Target raised | Outperform | $52 → $62 |
| 2026-09-09 | Citizens | Target raised | Market Outperform | $75 → $79 |
| 2026-09-09 | Wedbush | Target raised | Outperform | $42 → $50 |
| 2026-09-08 | HC Wainwright & Co. | Reiterated | Buy | $60 |
| 2026-09-08 | Wedbush | Reiterated | Outperform | $42 |
| 2026-08-13 | RBC Capital | Target raised | Outperform | $51 → $52 |
| 2026-08-13 | Guggenheim | Target raised | Buy | $39 → $40 |
| 2026-08-13 | Citizens | Target raised | Market Outperform | $74 → $75 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +33.4% | +101.2% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +33.5% | +15.0% |
| Volatility (annualized) | 53.0% | 101.2% |
| Max drawdown | -28.6% (Sep 2026→Oct 2026) | -92.8% (Jun 2022→Nov 2022) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 307.82 -2.21% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 90.9 +2.57% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.14 -3.28% · PRAX (Praxis Precision Medicines, Inc) USD 258.92 +0.96% · IONS (Ionis Pharmaceuticals, Inc.) USD 43.91 -0.81% · ABVX (Abivax SA) USD 90.23 -3.49%

## More
Full page: https://nexqual.com/PHVS · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.72 | $-0.66 | +8.9% | $0 | 11 |
| Next quarter (ends 2026-12-31) | $-0.77 | $-0.70 | +9.5% | $0 | 11 |
| Current fiscal year (ends 2026-12-31) | $-2.77 | $-2.62 | +5.9% | $0 | 13 |
| Next fiscal year (ends 2027-12-31) | $-2.72 | $-2.35 | +15.8% | $32.2M | 12 |